BeiGene Clinical Pipeline - Solid Tumor

For more information about this resource, please submit a medical information request.

We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage clinical drug candidates, four marketed products in China and one marketed product in the U.S.